[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Wu PP, Kuo SC, Huang WW, Yang JS, Lai KC, Chen HJ, Lin KL, Chiu YJ, Huang LJ, Chung JG: (-)-Epigallocatechin gallate induced apoptosis in human adrenal cancer NCI-H295 cells through caspase-dependent and caspase-independent pathway. Anticancer Res; 2009 Apr;29(4):1435-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (-)-Epigallocatechin gallate induced apoptosis in human adrenal cancer NCI-H295 cells through caspase-dependent and caspase-independent pathway.
  • Nevertheless, there are no reports to date about the molecular mechanisms and signal pathways of EGCG on the induction of apoptosis in human adrenal NCI-H295 cancer cells.
  • The purpose of this study was to investigate the anticancer effect and molecular mechanisms of EGCG on human adrenal NCI-H295 cancer cells.
  • The results showed that EGCG induced growth inhibition in a dose- and time-dependent manner.
  • When NCI-H295 cells were treated with 20 microM EGCG, the mitochondrial membrane potential decreased and intracellular free Ca(2+) increased in a time-dependent manner as analysed by flow cytometry.
  • EGCG promoted caspase-8, -9 and -3 activities in a time-dependent manner.
  • Based on the above findings, it was confirmed that EGCG may be a drug candidate for the treatment of human adrenal cancer in the future.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / pathology. Anticarcinogenic Agents / pharmacology. Apoptosis / drug effects. Caspases / metabolism. Catechin / analogs & derivatives
  • [MeSH-minor] Blotting, Western. Calcium / metabolism. Flow Cytometry. Humans. Membrane Potential, Mitochondrial / drug effects. Protease Inhibitors / pharmacology. Tumor Cells, Cultured


2. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell; 2004 Mar;5(3):221-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
  • Insulin-like growth factors and their receptor (IGF-1R) have been implicated in cancer pathophysiology.
  • We demonstrate that IGF-1R is universally expressed in various hematologic (multiple myeloma, lymphoma, leukemia) and solid tumor (breast, prostate, lung, colon, thyroid, renal, adrenal cancer, retinoblastoma, and sarcoma) cells.
  • Specific IGF-1R inhibition with neutralizing antibody, antagonistic peptide, or the selective kinase inhibitor NVP-ADW742 has in vitro activity against diverse tumor cell types (particularly multiple myeloma), even those resistant to conventional therapies, and triggers pleiotropic antiproliferative/proapoptotic molecular sequelae, delineated by global transcriptional and proteomic profiling.
  • NVP-ADW742 monotherapy or its combination with cytotoxic chemotherapy had significant antitumor activity in an orthotopic xenograft MM model, providing in vivo proof of principle for therapeutic use of selective IGF-1R inhibitors in cancer.
  • [MeSH-major] Hematologic Neoplasms / metabolism. Insulin-Like Growth Factor I / metabolism. Receptor, IGF Type 1 / antagonists & inhibitors. Receptor, IGF Type 1 / metabolism
  • [MeSH-minor] Antineoplastic Agents. Bone Marrow / metabolism. Enzyme Inhibitors / pharmacology. Flow Cytometry. Gene Expression Profiling. Humans. Multiple Myeloma. Neoplasms / drug therapy. Neoplasms / metabolism. Pyrimidines / pharmacology. Pyrroles / pharmacology. Transplantation, Heterologous / pathology. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • COS Scholar Universe. author profiles.
  • Nature Publishing Group. commentaries/discussion - Highlights from Nature Reviews Cancer .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15050914.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United States / PHS HHS / / P0-1 78378; United States / PHS HHS / / R0-1 50947
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ADW 742; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Pyrimidines; 0 / Pyrroles; 0 / Vascular Endothelial Growth Factor A; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


3. Tupikowski W, Bednarek-Tupikowska G, Florczak A: [Adrenocortical carcinoma and its treatment]. Postepy Hig Med Dosw (Online); 2004 Feb 26;58:27-36
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenocortical carcinoma and its treatment].
  • Adrenocortical carcinoma is a rare tumor with an annual incidence of 1 to 2 cases per million people.
  • It is a very aggressive tumor, with a median survival of 28 months, and is slightly more common in women (58.6%) than in men (41.4%).
  • Most adrenocortical neoplasms are hormone functional.
  • The rapid onset of Cushing 's syndrome, with its virilizing features, is characteristic of this cancer.
  • Adrenal tumors are often detected at an advanced stage.
  • Complete surgical resection is the only curative treatment for adrenal cancer.
  • Treatment also includes chemotherapy, especially with mitotane, usually in combination with doxorubicin, etoposide, and cisplatin.
  • Results of treatment are not satisfying, so adjuvant multicenter trials are still underway.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15069374.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 78E4J5IB5J / Mitotane; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 48
  •  go-up   go-down


Advertisement
4. Chan FK, Choi KL, Tiu SC, Shek CC, Au Yong TK: A case of giant malignant phaeochromocytoma. Hong Kong Med J; 2000 Sep;6(3):325-8
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of giant malignant phaeochromocytoma.
  • Malignant phaeochromocytoma is defined as the presence of tumour deposits at sites that are normally devoid of chromaffin cells.
  • We report on a 63-year-old man who had a giant malignant phaeochromocytoma of the right adrenal gland that encased the inferior vena cava.
  • The tumour was surgically unresectable by laparotomy.
  • This report alerts physicians of the methods of diagnosing and managing surgically unresectable malignant phaeochromocytoma.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11025856.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Radiopharmaceuticals; 0J45DE6B88 / Normetanephrine; 35MRW7B4AD / 3-Iodobenzylguanidine; RWM8CCW8GP / Octreotide
  •  go-up   go-down


5. Schteingart DE: Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res; 2000 Oct;33(10):1197-200
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conventional and novel strategies in the treatment of adrenocortical cancer.
  • Adrenocortical carcinoma is a highly malignant neoplasm with an incidence of two per million people per year.
  • Several treatment strategies have resulted in temporary or partial tumor regression but very few cases have attained long survival.
  • Surgical resection of the primary tumor and metastases is most effective.
  • Mitotane (o,p'-DDD) is an adrenalytic drug effective in inducing a tumor response in 33% of patients treated.
  • Mitotane requires metabolic transformation for therapeutic action.
  • Tumors may vary in their ability to metabolize mitotane and the ability of tumors to transform mitotane may predict the clinical response to the drug.
  • Preliminary data show a possible correlation between metabolic activity of neoplastic adrenocortical tissue and response to mitotane.
  • Future approaches to the treatment of adrenocortical carcinoma are likely to be based on blocking or reversing the biological mechanisms of tumorigenesis.
  • Angiogenic and chemotactic mechanisms may play a role in adrenal tumor growth and inhibition of these mechanisms may result in inhibition of tumor growth.
  • New mitotane analogs with greater adrenalytic potential could be a promising approach to developing more effective and selective therapies for adrenal cancer.
  • Alternative approaches should attempt to suppress tumor growth by means of compounds with anti-angiogenic and anti-chemotactic activity.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11004720.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


6. Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, Miceli R, Muleti A, Amendola D, Piergrossi P, Brunetti E, Toscano V, Stigliano A: Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr Relat Cancer; 2008 Jun;15(2):623-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
  • This drug and radiotherapy are used also in adrenal cancer treatment even if their biological action in this neoplasia remains unknown.
  • We investigated the effects of o,p'-DDD and ionizing radiations (IR) on cell growth inhibition and cell cycle perturbation in H295R and SW13 adrenocortical cancer cells.
  • Both cell lines were irradiated at a 6 Gy dose and were treated with o,p'-DDD 10(-5) M separately and with IR/o,p'-DDD in combination.
  • This combination treatment induced an irreversible inhibition of cell growth in both adrenocortical cancer cells.
  • In order to study the molecular mechanism involved in the G2 irreversible arrest, we have considered the H295R cell line showing the highest inhibition of cell proliferation associated with a noteworthy G2 arrest.
  • The kinase activity also shows an increase in the treated cells with combination therapy.
  • The same irreversible block on G2 phase, induced by IR/o,p'-DDD treatment, happened in H295R cells with restored wild-type p53 suggesting that this mechanism is not mediated by p53 pathway.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Antineoplastic Agents, Hormonal / pharmacology. Mitotane / pharmacology. Radiotherapy
  • [MeSH-minor] CDC2 Protein Kinase / metabolism. Cell Division / drug effects. Cell Division / radiation effects. Cell Line, Tumor. Cyclin B / metabolism. Cyclin B1. G2 Phase / drug effects. G2 Phase / radiation effects. Humans. RNA, Messenger / metabolism. Steroids / pharmacology. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. MITOTANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509009.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / CCNB1 protein, human; 0 / Cyclin B; 0 / Cyclin B1; 0 / RNA, Messenger; 0 / Steroids; 0 / Tumor Suppressor Protein p53; 78E4J5IB5J / Mitotane; EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


7. Narimoto K, Mizokami A, Izumi K, Mihara S, Sawada K, Sugata T, Shimamura M, Miyazaki K, Nishino A, Namiki M: Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. Int J Urol; 2010 Apr;17(4):337-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
  • OBJECTIVES: To analyze the clinical effects of flutamide as a second-line anti-androgen for combined androgen blockade in patients with castration-resistant prostate cancer (CRPC) initially treated with bicalutamide as a first-line anti-androgen.
  • METHODS: Our study population consisted of 16 patients with CRPC who were treated with flutamide (375 mg daily) as second-line hormonal therapy.
  • Dehydroepiandrosterone (DHEA), androstenedione, androstenediol, testosterone and dihydrotestosterone were measured to investigate the relationship between plasma androgens and outcome following treatment.
  • Furthermore, adrenal androgen levels in a medium of adrenal cancer cell line were also measured.
  • RESULTS: Second-line hormonal therapy using flutamide resulted in a reduction of the prostate-specific antigen (PSA) level in 14 (87.5%) of 16 patients.
  • In vitro, 3 micromol/L flutamide suppressed DHEA, androstenedione and androstenediol synthesis compared with bicalutamide in a medium of adrenal cancer cell line.
  • CONCLUSIONS: Our data show that flutamide suppresses the adrenal androgens in comparison with bicalutamide.
  • The responsiveness and response duration of flutamide can be predicted in patients with a higher baseline androstenediol level and a lower DHEA level.
  • Metabolites from adrenal androgens contribute to the progression of prostate cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Androgens / blood. Flutamide / therapeutic use. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adrenal Glands / secretion. Aged. Aged, 80 and over. Cell Line, Tumor. Humans. Male. Orchiectomy. Prognosis. Salvage Therapy


8. Kim HM, Ikeda M, Okano M, Miyoshi N, Hirose H, Yamashita S, Takemasa I, Mizushima T, Yamamoto H, Sekimoto M, Doki Y, Mori M: [A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2548-50
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy].
  • We report a case of 57-year-old woman suffering from advanced sigmoid colon cancer with adrenal and para-aortic lymph node recurrence.
  • Sigmoidectomy was performed for sigmoid colon cancer in January 2002.
  • She received a UFT + CPT-11 regimen as preoperative chemotherapy for liver metastasis (S2, S7) from December 2002.
  • A partial liver resection (S2, S7) was performed for liver metastasis in July 2003, and the UFT + CPT-11 was introduced as adjuvant chemotherapy.
  • However, adrenal and para-aortic lymph node recurrence was detected in February 2007, and mFOLFOX6 was performed as preoperative chemotherapy.
  • Right adrenalectomy and para-aortic lymph node dissection was performed in July 2007. mFOLFOX6 as postoperative chemotherapy was done, mFOLFOX6 + bevacizumab was started because of CEA increase.
  • The chemotherapy was performed for 23 courses and temporarily stopped due to adverse reactions, such as peripheral neuropathy (grade 2), general fatigue (grade 1), and nausea (grade 1).
  • She had no recurrence for almost 3 years after a resection of adrenal and para-aortic lymph node metastasis.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lymphatic Metastasis. Sigmoid Neoplasms / pathology. Sigmoid Neoplasms / therapy
  • [MeSH-minor] Adrenalectomy. Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Hepatectomy. Humans. Leucovorin / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Organoplatinum Compounds / therapeutic use. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224635.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 1548R74NSZ / Tegafur; 2S9ZZM9Q9V / Bevacizumab; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; 1-UFT protocol; Folfox protocol
  •  go-up   go-down


9. Schteingart DE, Benitez R, Bradford C, Narayan A, Wang S: Expression of anti-apoptosis genes determines the response of adrenal cancer to apoptosis-inducing chemotherapy. Anticancer Res; 2010 Dec;30(12):4805-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of anti-apoptosis genes determines the response of adrenal cancer to apoptosis-inducing chemotherapy.
  • BACKGROUND: This study tested the hypothesis that response of adrenal cortical carcinoma (ACC) to pro-apoptosis drugs depends on expression of anti-apoptosis genes.
  • MATERIALS AND METHODS: Expression of Bcl-2 and Bcl-XL proteins was determined in two human adrenal cancer cell lines, NCI-H-295 and RL-251.
  • Two pro-apoptosis drugs, gossypol (G) and docetaxel (D) were tested in vitro and in vivo in a human ACC/SCID mouse chimera.
  • CONCLUSION: This study provided proof of concept that expression of Bcl-XL determines response to pro-apoptosis drugs.
  • Profiling adrenal tumors for expression of anti-apoptosis genes may provide clues to their potential response to drugs that induce apoptosis.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / genetics. Apoptosis / drug effects. Apoptosis / genetics. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. bcl-X Protein / biosynthesis
  • [MeSH-minor] Animals. Cell Line, Tumor. Genes, bcl-2. Gossypol / pharmacology. Humans. Mice. Mice, SCID. Taxoids / pharmacology

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187456.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Taxoids; 0 / bcl-X Protein; 15H5577CQD / docetaxel; KAV15B369O / Gossypol
  •  go-up   go-down


10. Imataki O, Makimoto A, Kojima R, Sakiyama M, Hosono A, Takaue Y: Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases. Int J Clin Oncol; 2006 Apr;11(2):156-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases.
  • Adrenocortical carcinoma is a rare malignancy in adolescents and young adults.
  • The prognosis of unresectable/metastatic adrenocortical carcinoma remains very poor because the rarity of the tumor has made it difficult to establish treatment guidelines, and diagnosis and the resultant treatment can be greatly delayed.
  • We treated a 24-year-old woman who was diagnosed with adrenocortical carcinoma of the right adrenal gland which extended to the inferior vena cava.
  • Although she underwent surgical resection of the extensive tumor as the primary treatment, the disease recurred in the lung and liver as multiple metastases shortly after surgery.
  • She received intensive multimodality therapy, including chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP regimen), embolization of the feeding arteries, and proton irradiation for the liver mass.
  • Although this experience is limited, we suggest that TIP chemotherapy was effective for adrenocortical carcinoma, and a graft-versus-tumor effect after reduced-intensity stem cell transplantation may have contributed to the prolonged survival.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Liver Neoplasms / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Graft vs Host Disease. Humans


11. Kasperlik-Zaluska AA, Cichocki A: Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up. J Exp Ther Oncol; 2005;5(2):125-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
  • Our study aimed at evaluation of the relations between the plasma levels of mitotane (o,p'-DDD) and its metabolites, o,p'-DDA and o,p'-DDE, and the efficacy of Mitotane therapy during a long-term follow-up.
  • The o,p'-DDA/o,p'-DDD ratio rose significantly mainly in the first 1-3 months of therapy.
  • The o,p'-DDE levels rose slowly, reaching higher values in long-term therapy, over 12 months of mitotane administration.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents, Hormonal / blood. Mitotane / analogs & derivatives. Mitotane / blood

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471038.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 34113-46-7 / 2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid; 3424-82-6 / 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene; 78E4J5IB5J / Mitotane
  •  go-up   go-down


12. Tanaka K, Kumano Y, Kanomata N, Takeda M, Hara I, Fujisawa M, Kawabata G, Kamidono S: Oncocytic adrenocortical carcinoma. Urology; 2004 Aug;64(2):376-7
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 54-year-old man presented with a right subcostal mass.
  • Computed tomography demonstrated a massive tumor in the right abdomen.
  • Because renal or adrenal cancer was suspected, right adrenalectomy and nephrectomy were performed.
  • Five months postoperatively, multiple metastases had developed and were treated with surgical resection, chemotherapy, vascular embolization, and radiotherapy.
  • At last follow-up, the patient was alive with pulmonary and adrenal metastases and undergoing treatment with mitotane.
  • [MeSH-major] Adenocarcinoma / secondary. Adrenal Cortex Neoplasms / pathology
  • [MeSH-minor] Adrenalectomy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Embolization, Therapeutic. Etoposide / administration & dosage. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Mitotane / therapeutic use. Nephrectomy. Ribs / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15302503.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 78E4J5IB5J / Mitotane; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 7
  •  go-up   go-down


13. Nagase H, Yokouchi H, Ide Y, Okada K, Yanagisawa T, Mukai R, Ota H, Maruyama K, Murata K, Kinuta M: [The case of a person who was revealed by adrenal metastasis of pulmonary pleomorphic carcinoma]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2747-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The case of a person who was revealed by adrenal metastasis of pulmonary pleomorphic carcinoma].
  • Computed tomography revealed a tumor of right adrenal gland and a tumor of upper lobe of the right lung.
  • Adrenal tumor had rapidly increased, so we performed adrenectomy.
  • At first adrenal tumor was diagnosed as primary adrenal cancer because its histological findings did not coincide with those of common histologic types of lung cancer.
  • As there were possibilities that one of adrenal or lung tumor was primary and the other was metastatic or both of the two were double primary, we performed right upper lobectomy.
  • Lung tumor was diagnosed as primary pleomorphic carcinoma containing spindle-shaped tumor cells and adenocarcinoma, and then the diagnosis of adrenal tumor was corrected as metastasis of lung cancer.
  • Two months after the lung operation, cervical lymph node swelling, metastasis of stomach and local recurrence of adrenal tumor appeared.
  • After he underwent six courses of systemic chemotherapy of carboplatin and paclitaxel, a clinical complete response was obtained and no recurrence is observed for 4 years.
  • [MeSH-major] Adenocarcinoma / pathology. Adrenal Gland Neoplasms / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Adrenalectomy. Humans. Male. Middle Aged. Neoplasms, Unknown Primary / diagnosis. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224700.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Strosberg JR, Hammer GD, Doherty GM: Management of adrenocortical carcinoma. J Natl Compr Canc Netw; 2009 Jul;7(7):752-8; quiz 759
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenocortical carcinomas (ACCs) are rare tumors that arise from the cortex of the adrenal gland with an incidence 1 to 2 per million.
  • The rarity of this tumor translates into a paucity of experience in managing patients in most medical centers.
  • Because clinical series are small and prospective evaluation of treatment strategies is limited, the current state of knowledge is strongly influenced by expert consensus opinion from a few medical centers specializing in ACCs.
  • This article describes the basic diagnostic and prognostic issues in adrenal cancer management, and presents detailed rationales for therapeutic management.
  • [MeSH-major] Adrenal Cortex Neoplasms / therapy. Adrenocortical Carcinoma / therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Catecholamines / analysis. Chemotherapy, Adjuvant. Cushing Syndrome / drug therapy. Cushing Syndrome / etiology. Diagnostic Imaging. Humans. Hydrocortisone / analysis. Metanephrine / analysis. Mitotane / therapeutic use. Neoplasm Metastasis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19635227.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Catecholamines; 5001-33-2 / Metanephrine; 78E4J5IB5J / Mitotane; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


15. Montoya M, Brown JW, Fishman LM: Comparative effects of chemotherapeutic agents on the growth and survival of human adrenal carcinoma cells in culture. Horm Metab Res; 2008 May;40(5):302-5
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative effects of chemotherapeutic agents on the growth and survival of human adrenal carcinoma cells in culture.
  • Adrenocortical carcinoma is an uncommon malignancy that is usually fatal within a short time after diagnosis.
  • We have investigated the effects on the growth and survival of SW-13 human adrenal carcinoma cells in culture of some currently used and some potentially new agents in the treatment of adrenal cancer.
  • Established drugs tested were mitotane, cisplatin, etoposide, 5-fluorouracil, and suramin.
  • All the other agents tested required much higher doses for effect, including mitotane, the current most commonly used chemotherapy for adrenal cancer, with an EC (50) of 3.3x10 (-4) M.
  • These data suggest that paclitaxel, 2-methoxyestradiol, and cytosine arabinofuranoside should be further evaluated for their potential in the chemotherapy of adrenal carcinoma.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor / methods. Humans

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18491247.001).
  • [ISSN] 0018-5043
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Horstmann M, Merseburger AS, Stenzl A, Kuczyk M: [Systemic therapy of malignant adrenal tumors]. Urologe A; 2006 May;45(5):605-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Systemic therapy of malignant adrenal tumors].
  • [Transliterated title] Systemische Therapie maligner Nebennierentumoren.
  • Systemic treatment of advanced-stage adrenal malignancies is most often only palliative.
  • Mitotane alone or in combination with other chemotherapeutic agents such as cisplatin, etoposide, and vincristine are established therapeutic concepts for the treatment of metastatic adrenal cancer.
  • New therapeutic options are tumor vaccination and treatment with antiangiogenic drugs.
  • Metaiodobenzylguanidine as a radiotherapeutic drug or chemotherapeutic combination therapies that include cyclophosphamide, vincristine, and dacarbazine are applied for systemic treatment of malignant pheochromocytomas.. However, the clinical efficacy of the latter regimen needs further evaluation.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / methods. Neoplasm Recurrence, Local / prevention & control. Palliative Care / methods. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):497-504 [2380344.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1533-5 [8111724.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):657-66 [16172198.001]
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] Eur J Surg Oncol. 2003 Apr;29(3):278-83 [12657240.001]
  • [Cites] J Endocrinol Invest. 1997 Dec;20(11):648-58 [9492103.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):667-80 [16172199.001]
  • [Cites] Cancer. 2002 May 1;94(9):2333-43 [12015757.001]
  • [Cites] J Nucl Biol Med. 1991 Oct-Dec;35(4):269-76 [1823834.001]
  • [Cites] Tumori. 1992 Oct 31;78(5):345-8 [1494808.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):161-5 [8418229.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] J Clin Oncol. 1989 Apr;7(4):499-508 [2926472.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1398-403 [2949824.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1281-7 [11106117.001]
  • [Cites] JAMA. 1973 Mar 5;223(10):1109-12 [4739370.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1159-65 [10699907.001]
  • [Cites] Am J Clin Oncol. 1999 Aug;22(4):364-70 [10440191.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3145-55 [8242539.001]
  • [Cites] Curr Probl Cancer. 1985 May;9(5):1-89 [3021396.001]
  • [Cites] Pharmacol Res. 2002 Dec;46(6):551-5 [12457630.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2001 Jul;92(5):593-6 [11517573.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(5):361-6 [11716230.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Sep;41(3):299-307 [7955436.001]
  • [Cites] Endocr Rev. 2003 Oct;24(5):600-32 [14570746.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1317-24 [9141510.001]
  • [Cites] Hypertension. 1985 Jan-Feb;7(1):118-24 [3980054.001]
  • [Cites] Surgery. 1997 Dec;122(6):1212-8 [9426440.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:54-60 [12381541.001]
  • [Cites] Ann Intern Med. 1988 Aug 15;109(4):267-73 [3395037.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Apr;76(4):1019-24 [8473376.001]
  • (PMID = 16622644.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 31
  •  go-up   go-down


17. Bastida CM, Tejada F, Cremades A, Peñafiel R: Aminoglutethimide, a steroidogenesis inhibitor, abolishes hormonal induction of ornithine decarboxylase in steroidogenic tissues: evidence for its role as cAMP-dependent protein kinase inhibitor. Biochem Biophys Res Commun; 2001 Feb 16;281(1):244-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aminoglutethimide, a steroidogenesis inhibitor, abolishes hormonal induction of ornithine decarboxylase in steroidogenic tissues: evidence for its role as cAMP-dependent protein kinase inhibitor.
  • Aminoglutethimide (AMG), a potent inhibitor of steroidogenesis used in the treatment of breast cancer and some adrenal pathologies, abolished the induction of ornithine decarboxylase (ODC) elicited by peptide hormones and by dibutyryl-cAMP in steroidogenic tissues.
  • This inhibition may explain some of the effects observed in AMG treatment which cannot be ascribed to its direct effect on the cytochrome P450scc complex or aromatase.
  • Taking into account that ODC, the rate-limiting enzyme in polyamine synthesis, is elevated in many types of cancer and that overexpression of this enzyme is associated with cell transformation, one may speculate that the inhibitory action of AMG on protein kinase A represents a positive colateral effect of this drug in cancer therapy.
  • [MeSH-minor] Adrenal Glands / drug effects. Adrenocorticotropic Hormone / pharmacology. Animals. Aromatase / metabolism. Chorionic Gonadotropin / blood. Chorionic Gonadotropin / metabolism. Chorionic Gonadotropin / pharmacology. Cytochrome P-450 Enzyme System / metabolism. Dose-Response Relationship, Drug. Enzyme-Linked Immunosorbent Assay. Female. Gonads / drug effects. Humans. Inhibitory Concentration 50. Ketoconazole / pharmacology. Male. Mice. Ovary / metabolism. Polyamines / metabolism. Testis / metabolism

  • Hazardous Substances Data Bank. AMINOGLUTETHIMIDE .
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11178987.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Enzyme Inhibitors; 0 / Polyamines; 0O54ZQ14I9 / Aminoglutethimide; 9002-60-2 / Adrenocorticotropic Hormone; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Aromatase; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 4.1.1.17 / Ornithine Decarboxylase; R9400W927I / Ketoconazole
  •  go-up   go-down


18. Niaz WA, Alvi S: Metastatic malignant pheochromocytoma of adrenal gland. J Coll Physicians Surg Pak; 2008 May;18(5):305-7
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic malignant pheochromocytoma of adrenal gland.
  • Malignant pheochromocytoma is a rare disease with a high mortality.
  • Surgical removal is usually curative while chemotherapy and radiotherapy are palliative treatments.
  • A case of metastatic malignant pheochromocytoma of the right adrenal gland is presented who had fluctuating blood pressure with episodic headache and raised urinary VMA levels.
  • Thoraco-abdominal resection of the tumour resulted in control of blood pressure and patient was asymptomatic at 4 months follow-up.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Pheochromocytoma / secondary
  • [MeSH-minor] Adrenalectomy / methods. Adult. Follow-Up Studies. Humans. Male. Neoplasm Metastasis. Severity of Illness Index. Tomography, X-Ray Computed. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541088.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


19. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB: Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res; 2009 Sep;41(9):697-702
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
  • They may be benign or malignant but the pathological distinction is mainly made when metastases are present.
  • Available treatments in the form of surgery, chemotherapy, and radionuclide therapy may improve symptoms and biochemical markers, but the results for the control of tumour bulk are less favourable.
  • Furthermore, responses to treatment are frequently short-lived.
  • This short review outlines the main molecular and histological features of malignant phaeochromocytoma and the difficulties in differentiating between benign and malignant disease.
  • We list current therapies used for malignant pheochromocytoma; however, these generally achieve relatively low success rates.
  • Hence, there is a need for new and more effective therapies.
  • In vitro studies have implicated the PI3/Akt/mTOR pathway in the pathogenesis of malignant NETS, including phaeochromocytoma.
  • We have used RAD001 in four patients with progressive malignant paraganglioma/phaeochromocytoma in addition to other therapies (with institutional approval for compassionate use), and evaluated the effects of this treatment.
  • We outline these four cases and review the theoretical background for this therapy, although the outcomes were relatively disappointing.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Pheochromocytoma / drug therapy. Protein Kinase Inhibitors / therapeutic use. Sirolimus / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Everolimus. Female. Humans. Male. Protein Kinases / metabolism. Signal Transduction / drug effects. TOR Serine-Threonine Kinases. Young Adult

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424940.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 9HW64Q8G6G / Everolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


20. Plouin PF, Amar L, Lepoutre C: Phaeochromocytomas and functional paragangliomas: clinical management. Best Pract Res Clin Endocrinol Metab; 2010 Dec;24(6):933-41
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phaeochromocytomas (PH) and functional paragangliomas (FPGL) are neoplasms of adrenal (PH) or extra-adrenal (FPGL) chromaffin tissue that synthesize catecholamines.
  • Catecholamines are converted into inactive metabolites, metanephrines, within the tumour and the diagnosis of PH/FPGL is therefore based on the quantification of plasma or urinary metanephrines.
  • The tumour can be located by computed tomography, magnetic resonance imaging and metaiodobenzylguanidine scintigraphy.
  • Patients are treated by tumour resection following alpha-blockade.
  • PH and FPGL may be sporadic or part of several genetic diseases.
  • Patients with PH/FPGL should be followed up indefinitely as the disease may recur, particularly if they have inherited or extra-adrenal tumours.
  • About 10% of tumours are malignant either at initial surgery or during follow-up.
  • Recurrences and malignancy are more frequent in cases with large or extra-adrenal tumours, and in SDHB mutation carriers.
  • Treatments for progressive malignant PH/FPGL include tumour debulking, metabolic radiotherapy, chemotherapy, and possibly tyrosine kinase inhibitors.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / therapy. Paraganglioma / diagnosis. Paraganglioma / therapy. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 21115162.001).
  • [ISSN] 1878-1594
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


21. Sfaxi M, Bouzouita A, Bouasker I, Kourda N, Ben Slama MR, Ben Jilani Baltaji S, Chebil M: [Primary bilateral adrenal T-cell lymphoma. A case report rarer than B-cell lymphoma]. Ann Endocrinol (Paris); 2008 Jun;69(3):249-53
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary bilateral adrenal T-cell lymphoma. A case report rarer than B-cell lymphoma].
  • [Transliterated title] Lymphome surrénalien primitif bilatéral de phénotype T. Un cas clinique beaucoup plus rare que le lymphome B.
  • Primary adrenal lymphoma is a rare condition.
  • Adrenal lymphoma is often bilateral and in most of the cases of B-cell type.
  • The prognosis is bad and patient can die early because of acute adrenal insufficiency.
  • We report a case of a 70-year-old man who was admitted for acute adrenal insufficiency due to primary bilateral adrenal T-cell lymphoma.
  • Clinical features and imaging are not specific. (18)F-FDG PET Scan is an excellent mean to detect malignant tumor of adrenal gland.
  • The standard treatment is chemotherapy.
  • [MeSH-major] Adrenal Gland Neoplasms / radionuclide imaging. Lymphoma, T-Cell / radionuclide imaging
  • [MeSH-minor] Aged. Fatal Outcome. Fluorodeoxyglucose F18. Humans. Immunohistochemistry. Incidence. Lymphoma, B-Cell / epidemiology. Male. Multiple Organ Failure. Positron-Emission Tomography. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455145.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


22. Schreinemakers JM, van Dam PS, Seldenrijk CA, Biesma DH, Borel Rinkes IH: [The adrenocortical carcinoma, a tumour of wide clinical diversity]. Ned Tijdschr Geneeskd; 2004 Oct 23;148(43):2109-13
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The adrenocortical carcinoma, a tumour of wide clinical diversity].
  • [Transliterated title] Het bijnierschorscarcinoom, een tumor met een grote klinische verscheidenheid.
  • Over the course of a few years, an obese 52-year-old woman with a 23-year history of hypertension developed a number of abdominal complaints including gall stones.
  • Her blood pressure became increasingly difficult to control and she developed diabetes mellitus and suffered palpitations and headaches.
  • CT-scan showed a large inhomogeneous mass of nine centimetres in her left adrenal gland, which was subsequently removed surgically.
  • The histopathological diagnosis was consistent with an adenoma.
  • After a number of months the patient developed bone and liver metastases and the diagnosis was amended to carcinoma of the adrenal cortex.
  • She then underwent radiotherapy and chemotherapy treatment.
  • One year after surgery she developed a pancytopenia and died.
  • Surgical resection is the only curative therapy.
  • It may be difficult to distinguish between benign and malignant cortical tumours.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis
  • [MeSH-minor] Bone Neoplasms / secondary. Diagnosis, Differential. Fatal Outcome. Female. Humans. Liver Neoplasms / secondary. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553352.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Bruni R, Nigita G, Pagani Guazzugli Bonaiuti V, Petrocca S, Terenzi A: Adrenal metastatic placental site trophoblastic tumor. Case report. Chir Ital; 2003 Mar-Apr;55(2):257-60
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal metastatic placental site trophoblastic tumor. Case report.
  • Placental site trophoblastic tumor is a rare disease.
  • Initially considered a benign pathology, its malignant potential with metastases was later recognized.
  • The therapy is surgical and in cases of metastatised disease has to be supplemented by chemotherapy.
  • A case of placental site trophoblastic tumour with a single metastasis to the left adrenal gland treated with adrenalectomy and chemotherapy is reported.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Adrenalectomy. Trophoblastic Tumor, Placental Site / secondary. Trophoblastic Tumor, Placental Site / therapy. Uterine Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Pregnancy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12744102.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Syrigos KN, Vile RG, Peters AM, Harrington KJ: Biodistribution and pharmacokinetics of 111In-dTPA-labelled pegylated liposomes after intraperitoneal injection. Acta Oncol; 2003;42(2):147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes (IDLPL) and unencapsulated 111In-DTPA administered by the intraperitoneal (i.p.) and i.v. routes in non-tumour-bearing mice were compared.
  • A variety of tissues were dissected from 5 min to 192 h to determine the biodistribution and pharmacokinetics.
  • Injection of IDLPL via the i.p. route caused a 74-fold increase in the area under the concentration (AUC) versus time curve in the peritoneum compared to unencapsulated 111In-DTPA.
  • Similarly, the AUC for all the intra-abdominal tissues was increased significantly (20-427-fold).
  • colon (1.2-fold), gallbladder (5.1-fold) and adrenal gland (2.1-fold).
  • These data support the development of i.p. liposomal chemotherapy for the treatment of intraperitoneal malignant disease.
  • [MeSH-minor] Adrenal Glands / metabolism. Animals. Area Under Curve. Chemistry, Pharmaceutical. Colon / metabolism. Drug Carriers. Drug Delivery Systems. Female. Gallbladder / metabolism. Injections, Intraperitoneal. Injections, Intravenous. Intestine, Small / metabolism. Liposomes. Mice. Ovary / metabolism. Pancreas / metabolism. Peritoneum / metabolism. Specific Pathogen-Free Organisms. Stomach / metabolism. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12801133.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Indium Radioisotopes; 0 / Liposomes; 7A314HQM0I / Pentetic Acid
  •  go-up   go-down


25. Fernández Sarabia MT, Rodríguez García JM, Cardenal Escarcena A, Serrano Vicente J, García Bernardo L: Adrenal metastasis of breast cancer with involvement of the inferior vena cava. Clin Transl Oncol; 2008 Nov;10(11):761-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal metastasis of breast cancer with involvement of the inferior vena cava.
  • Tumour thrombosis of the inferior cava vein is usually associated with primary renal cell cancer.
  • To our knowledge, this is the first case reported of adrenal metastasis of breast cancer extending into the inferior vena cava.
  • There are few references in the literature documenting this extension with positron emission tomography (PET) and enhanced computed tomography (CT).
  • The authors focus on the role of combined PET-CT imaging in the accurate detection of malignant thrombus.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Breast Neoplasms / pathology. Carcinoma / secondary. Renal Veins / pathology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Adult. Anticoagulants / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Capecitabine. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Lymph Node Excision. Mastectomy, Radical. Neoplasm Invasiveness. Radiography. Radiotherapy, Adjuvant. Venous Thrombosis / diagnostic imaging. Venous Thrombosis / drug therapy. Venous Thrombosis / etiology

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nucl Med. 2005 May;30(5):342-3 [15827409.001]
  • [Cites] Br J Radiol. 2004 Oct;77(922):888-90 [15483006.001]
  • [Cites] Radiographics. 1999 Jan-Feb;19(1):61-77; quiz 150-1 [9925392.001]
  • [Cites] Clin Nucl Med. 2005 May;30(5):338-9 [15827407.001]
  • [Cites] Abdom Imaging. 1994 Jul-Aug;19(4):359-60 [8075565.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1949-56 [15143089.001]
  • [Cites] Ugeskr Laeger. 2001 Sep 17;163(38):5209-11 [11577529.001]
  • [Cites] World J Gastroenterol. 2008 Feb 28;14(8):1212-7 [18300346.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jul-Aug;28(4):517-9 [15232383.001]
  • (PMID = 19015074.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Gedik GK, Hoefnagel CA, Bais E, Olmos RA: 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging; 2008 Apr;35(4):725-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
  • The experience with its therapeutic use is limited.
  • We report our experience for the treatment of malignant phaeochromocytoma and paraganglioma.
  • MATERIALS AND METHODS: The charts of 19 patients with malignant phaeochromocytoma (n = 12) or paraganglioma (n = 7), who were treated with (131)I-MIBG, were retrospectively reviewed.
  • Four patients (21%) received radiotherapy, three (16%) chemotherapy, and in one patient (5%), both chemotherapy and radiotherapy was given before (131)I-MIBG therapy.
  • Response to (131)I-MIBG treatment was evaluated by objective as tumour response, biochemical and subjective response.
  • Objective tumour response was achieved in 47% of the patients.
  • Overall median follow-up was 29 months, with a range of 3-93 months.
  • CONCLUSION: Our data support that symptomatic and biochemical response can be reached with (131)I-MIBG therapy in patients with metastatic phaeochromocytoma and paraganglioma.
  • Although complete tumour response was not observed, the palliation and control of tumour function by (131)I-MIBG therapy may be valuable for the patients.
  • [MeSH-major] 3-Iodobenzylguanidine / therapeutic use. Adrenal Gland Neoplasms / radiotherapy. Antineoplastic Agents / therapeutic use. Paraganglioma / radiotherapy. Pheochromocytoma / radiotherapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Thoracic Neoplasms / mortality. Thoracic Neoplasms / radiotherapy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):685-93 [11158032.001]
  • [Cites] Eur J Nucl Med. 1988;14(7-8):345-8 [3181183.001]
  • [Cites] J Endocrinol Invest. 1997 Dec;20(11):648-58 [9492103.001]
  • [Cites] Eur J Nucl Med. 1994 Jun;21(6):561-81 [7915987.001]
  • [Cites] J Nucl Biol Med. 1991 Oct-Dec;35(4):318-20 [1823846.001]
  • [Cites] Curr Opin Oncol. 2005 Jan;17(1):13-8 [15608506.001]
  • [Cites] N Engl J Med. 1981 Jul 2;305(1):12-7 [7231514.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:498-504 [17102117.001]
  • [Cites] Surgery. 2003 Dec;134(6):956-62; discussion 962-3 [14668728.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):239-48 [12872341.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jul;55(1):47-60 [11453952.001]
  • [Cites] J Nucl Med. 1984 Feb;25(2):197-206 [6726430.001]
  • [Cites] Hong Kong Med J. 2000 Sep;6(3):325-8 [11025856.001]
  • [Cites] Ann Intern Med. 1988 Aug 15;109(4):267-73 [3395037.001]
  • (PMID = 18071700.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


27. Schuppert F, Berger D, Peters H, Schröder S, Schöfl C, Tischler J, Hiller WF, von zur Mühlen A: [A young woman with neurofibromatosis 1 (Recklinghausen disease), abdominal tumor and hypertension]. Dtsch Med Wochenschr; 2000 Nov 17;125(46):1390-4
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A young woman with neurofibromatosis 1 (Recklinghausen disease), abdominal tumor and hypertension].
  • [Transliterated title] Eine junge Patientin mit Neurofibromatose Typ 1 (Morbus Recklinghausen), Unterbauchtumor und Hypertonus.
  • HISTORY AND ADMISSION FINDINGS: A 38-year-old woman, known to have type 1 neurofibromatosis (NF1; von Recklinghausen's disease) and recurrence of a malignant haemangiopericytoma in the lower abdomen developed hypertension.
  • Physical examination revealed tachycardia and paleness of the distal digits, in addition to multiple neurofibromas and café-au-lait spots.
  • INVESTIGATIONS: A tumour was found in the region of the right adrenal gland, in addition to the known haemangiopericytoma.
  • TREATMENT AND COURSE: Because of the extensive local changes the recurrent haemangiopericytoma was only partially resected.
  • At the same time a right adrenalectomy was performed without complication.
  • Instead she was given weekly palliative chemotherapy with adriamycin, with little improvement.
  • She died several weeks later from the malignancy.
  • [MeSH-major] Abdominal Neoplasms / surgery. Hemangiopericytoma / surgery. Hypertension / complications. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / diagnosis. Neurofibromatosis 1 / diagnosis
  • [MeSH-minor] Adrenal Gland Neoplasms / diagnosis. Adult. Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Exons. Fatal Outcome. Female. Humans. Nerve Tissue Proteins / genetics. Neurofibromin 1. Palliative Care. Pheochromocytoma / diagnosis. Skin Neoplasms / diagnosis. Tachycardia

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11129996.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nerve Tissue Proteins; 0 / Neurofibromin 1; 80168379AG / Doxorubicin
  •  go-up   go-down


28. Chew SL: Recent developments in the therapy of phaeochromocytoma. Expert Opin Investig Drugs; 2004 Dec;13(12):1579-83
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent developments in the therapy of phaeochromocytoma.
  • The basic principles of treatment for phaeochromocytomas and paragangliomas are to block the effects of high catecholamines and make the patient safe for surgical removal of the tumour.
  • High-dose [(131)I]-metaiodobenzylguanidine therapy and combined [(131)I]-metaiodobenzylguanidine and chemotherapy are promising new developments for the malignant disease.
  • All patients should be followed indefinitely because the recurrence or malignancy rate is >or= 10% over a prolonged follow up.
  • [MeSH-major] 3-Iodobenzylguanidine / therapeutic use. Adrenal Gland Neoplasms / therapy. Combined Modality Therapy / trends. Pheochromocytoma / therapy
  • [MeSH-minor] Catecholamines / metabolism. Humans. Paraganglioma / therapy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15566315.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Catecholamines; 35MRW7B4AD / 3-Iodobenzylguanidine
  • [Number-of-references] 40
  •  go-up   go-down


29. Emmert S, Zutt M, Haenssle H, Neumann C, Kretschmer L: Inefficacy of vindesine monotherapy in advanced stage IV malignant melanoma patients previously treated with other chemotherapeutic agents. Melanoma Res; 2003 Jun;13(3):299-302
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inefficacy of vindesine monotherapy in advanced stage IV malignant melanoma patients previously treated with other chemotherapeutic agents.
  • The anti-melanoma activity of vindesine as a single or polychemotherapeutic agent has been reported previously in adjuvant and first-line melanoma treatment.
  • In this study, we investigated the usefulness of vindesine monotherapy as salvage therapy in stage IV melanoma patients after failure of other chemotherapies.
  • Previous systemic treatment consisted of polychemotherapy or combined chemo-immunotherapy.
  • All 13 patients suffered from visceral metastases (three lung, one liver, one adrenal gland and eight multiple visceral metastases).
  • A median of three vindesine treatments was administered.
  • Despite the various pre-treatments, the toxicity of vindesine was mild.
  • In all 13 patients, vindesine treatment was stopped due to disease progression.
  • The median survival after primary tumour diagnosis was 42 months (8-151 months), the survival after entering stage IV was 11 months (3-35 months), and the survival after starting vindesine therapy was 4 months (1-22 months).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Melanoma / drug therapy. Melanoma / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Vindesine / therapeutic use
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged. Neoplasm Staging. Salvage Therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12777986.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; RSA8KO39WH / Vindesine
  •  go-up   go-down


30. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli A: Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab; 2009 Apr;23(2):233-43
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adrenal incidentaloma.
  • Clinically inapparent adrenal masses, or adrenal incidentalomas, are discovered inadvertently in the course of work-up or treatment of unrelated disorders.
  • Cortical adenoma is the most frequent tumour detected incidentally, but adrenocortical cancer, phaeochromocytoma and metastasis are not rare.
  • Two critical questions should be answered before trying to outline the management of adrenal incidentaloma:.
  • (1) identify either primary (adrenocortical cancer) or secondary (adrenal metastasis) malignancy;.
  • Radiological evaluation is the key to the differential diagnosis of benign and malignant tumours.
  • Endocrine testing is necessary to exclude phaeochromocytoma in all patients with an adrenal incidentaloma because this tumour may remain undiagnosed after imaging studies.
  • The management of clinically inapparent adrenal adenomas may vary depending whether or not they are functioning.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / drug therapy. Adenoma / therapy. Animals. Humans. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500766.001).
  • [ISSN] 1878-1594
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 46
  •  go-up   go-down


31. Widimský J Jr, Zelinka T, Petrák O, Strauch B, Rosa J, Michalský M, Kasalický M, Safarík L, Vranková A, Holaj R: [Pheochromocytoma: diagnosis and treatment]. Cas Lek Cesk; 2009;148(8):365-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pheochromocytoma: diagnosis and treatment].
  • Pheochromocytoma (pheo) is adrenal or less frequently extraadrenal tumour of chromafine tissue.
  • Proper diagnosis of pheo is thus of utmost importance.
  • 24-h blood pressure (BP) monitoring may contribute to the diagnosis of pheo due to increased BP variability and absence of night BP decline.
  • Morphological diagnosis of adrenal/extraadrenal pheo is based on CT/MR visualisation and 123I-metaiodobenzylguanidin (MIBG) or PET 18F-fluorodeoxyglucose scan.
  • Genetic analysis should be performed in all confirmed pheo cases, especially in younger subjects below 50 years of age in order to detect mutations of following genes: von Hippel-Lindau (VHL), RET- protooncogen, genes encoding B, C and D subunit of mitochondrial sukcinat dehydrogenaze (SDHB, SDHC, SDHD) and neurofibromatosis type I gene.
  • Pharmacological treatment is based on alpha blockers with subsequent (after 24-48 hours) administration of beta-blockers/especially in patients with tendency to tachycardia/.
  • Following this therapy normalisation of BP is common and laparoscopic excision of pheo tumour can be realised.
  • Malignant pheos are difficult to treat due to early occurrence of metastasis and lack of response to chemotherapy or iradiation in most cases.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy
  • [MeSH-minor] Diagnosis, Differential. Humans


32. Grozinsky-Glasberg S, Grossman AB, Korbonits M: The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol; 2008 May 14;286(1-2):238-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of somatostatin analogues in the treatment of neuroendocrine tumours.
  • Neuroendocrine tumours belong to a heterogeneous family of neoplasms, originating in endocrine glands (such as the pituitary, parathyroid or the neuroendocrine adrenal glands), in endocrine islets (within the thyroid or pancreas) as well as in endocrine cells dispersed between exocrine cells throughout the digestive or respiratory tracts.
  • The clinical behaviour of neuroendocrine tumours is variable; they may be functioning or not functioning, ranging from well-differentiated slow growing neuroendocrine tumours to poorly differentiated neuroendocrine tumours, which are highly aggressive malignant tumours.
  • The development of somatostatin analogues as important diagnostic and treatment tools have revolutionised the clinical management of patients with neuroendocrine tumours.
  • However, although symptomatic relief and stabilisation of tumour growth for various periods of time are observed in many patients treated with somatostatin analogues, tumour regression is rare.
  • Development of new somatostatin analogues and new drug combination therapies should further improve the clinical management of these patients.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Neuroendocrine Tumors / drug therapy. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use
  • [MeSH-minor] Adrenal Gland Neoplasms / drug therapy. Carcinoma, Bronchogenic / drug therapy. Female. Humans. Ovarian Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Paraganglioma / drug therapy. Pheochromocytoma / drug therapy. Pituitary Neoplasms / drug therapy. Thyroid Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18037561.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 51110-01-1 / Somatostatin
  • [Number-of-references] 75
  •  go-up   go-down


33. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB: The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer; 2007 Sep;14(3):569-85
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
  • Malignant phaeochromocytomas are rare tumours accounting for ~10% of all phaeochromocytomas; the prevalence of malignancy among paragangliomas is higher, especially those associated with succinate dehydrogenase subunit B gene mutations.
  • Although a subset of these tumours has metastatic disease at initial presentation, a significant number develops metastases during follow-up after excision of an apparently benign tumour.
  • Clinical, biochemical and histological features cannot reliably distinguish malignant from benign tumours.
  • Several imaging modalities have been utilised for the diagnosis and staging of these tumours.
  • Functional imaging using radiolabelled metaiodobenzylguanidine (MIBG) and more recently, (18)F-fluorodopamine and (18)F-fluorodopa positron emission tomography offer substantial sensitivity and specificity to correctly detect metastatic phaeochromocytoma and paraganglioma and helps identify patients suitable for treatment with radiopharmaceuticals.
  • The 5-year mortality rate of patients with malignant phaeochromocytomas and paragangliomas greater than 50% indicates that there is considerable room for the improvement of currently available therapies.
  • The main therapeutic target is tumour reduction and control of symptoms of excessive catecholamine secretion.
  • Currently, the best adjunctive therapy to surgery is treatment with radiopharmaceuticals using (131)I-MIBG; however, this is very rarely curative.
  • Chemotherapy has been used for metastatic disease with only a partial and mainly palliative effect.
  • The role of other forms of radionuclide treatment either alone or in combination with chemotherapy is currently evolving.
  • Ongoing microarray studies may provide novel intracellular pathways of importance for proliferation/cell cycle control, and lead to the development of novel pharmacological agents.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / therapy. Paraganglioma / diagnosis. Paraganglioma / therapy. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy
  • [MeSH-minor] Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Chromaffin Cells / pathology. Combined Modality Therapy. Endocrine Surgical Procedures. Humans. Radiopharmaceuticals / therapeutic use. Radiotherapy / trends

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914089.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals
  • [Number-of-references] 159
  •  go-up   go-down


34. Schteingart DE: Adjuvant mitotane therapy of adrenal cancer - use and controversy. N Engl J Med; 2007 Jun 7;356(23):2415-8
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant mitotane therapy of adrenal cancer - use and controversy.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2007 Sep 20;357(12):1257-8; author reply 1259 [17891838.001]
  • [CommentOn] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • (PMID = 17554125.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down






Advertisement